8:08 PM
 | 
Dec 14, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA accepts Regeneron's sBLA for 12-week Eylea dosing

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted an sBLA for a quarterly dosing schedule of Eylea aflibercept to treat wet age-related macular degeneration (AMD). Its PDUFA date...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >